BioNTech and DualityBio announced that their Phase 3 trial DYNASTY-Breast02 met its primary endpoint, showing a statistically significant but modest improvement in progression-free survival (PFS) for trastuzumab pamirtecan compared to chemotherapy in HR+/HER2-low metastatic breast cancer patients who progressed on endocrine therapy. Overall survival data are not yet mature, and a higher rate of interstitial lung disease was observed, mostly mild to moderate. The safety profile aligns with previous trials, but the benefit may be limited in the current treatment landscape. The companies plan to review the data and decide on next steps.
Following the announcement of positive Phase 3 trial results for trastuzumab pamirtecan by BioNTech and DualityBio, BioNTech's stock on Pluang is trading at USD 86.58 as of Oct 26, 2026 16:11 WIB, down 1.74% for the day. The stock's market cap stands at $22.13 billion, with a 52-week range between $83.89 and $119.34. Typical investors hold BNTX shares for about 60 days on the platform.
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
BioNTech and Bristol Myers Squibb reported promising Phase 2 results for pumitamig combined with docetaxel in advanced non-small cell lung cancer (NSCLC) patients who progressed after immunotherapy plus chemotherapy. The treatment showed a confirmed ...
Moderna's stock dropped 25% after a late-stage melanoma vaccine report was briefly posted online and then removed. The vaccine, developed with Merck, showed favorable results in reducing melanoma recurrence or death when combined with Keytruda, but t...
BioNTech announced a collaboration with Gilead Sciences to test pumitamig combined with sacituzumab govitecan in a Phase 3 trial for PD-L1 low or negative triple-negative breast cancer (TNBC). This trial, ROSETTA Breast-01, will replace chemotherapy ...
